Acitretin Plasma Levels Under Hemodialysis

Status Withdrawn

Clinical Trial Summary

Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year.

Clinical Trial Description

Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year. Plasma levels of acitretin will be monitored and influence of hemodialysis on acitretin plasma levels will be determined. Number of in-situ or invasive squamous cell carcinoma of the skin cases will be determined.

- Trial with medicinal product ;

Study Design

Related Conditions & MeSH terms

Carcinoma, Squamous Cell

Clinical Trial Details

NCT number	NCT00488384
Study type	Interventional
Source	University of Zurich
Contact
Status	Withdrawn
Phase	Phase 4
Start date	June 2007
Completion date	June 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02743832` - A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.	N/A
Active, not recruiting	`NCT02229656` - Olaparib and Radiotherapy in Head and Neck Cancer	Phase 1
Completed	`NCT00389727` - Simultaneous Integrated Boost (SIB)- IMRT	Phase 2
Recruiting	`NCT02328391` - STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE	N/A
Completed	`NCT00875381` - Analysis of Melanocytes (Pigment Cells) in Sun-Exposed Skin	N/A
Completed	`NCT00534950` - Randomized Multicenter Study of 5 vs 6 Weekly Fraction of RT in the Treatment of SCC of the Head and Neck	N/A
Terminated	`NCT00073450` - Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)	Phase 2
Terminated	`NCT01441128` - -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer	Phase 1
Recruiting	`NCT05970497` - A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors	Phase 1
Completed	`NCT01362127` - Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia	Phase 2
Completed	`NCT00240682` - Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR	Phase 2
Terminated	`NCT02254044` - Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus	Phase 1
Active, not recruiting	`NCT00829192` - Phase II AK Study in Organ Transplant Patients	Phase 2
Completed	`NCT00313027` - Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation	N/A
Completed	`NCT00539630` - TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN	Phase 3
Recruiting	`NCT04564989` - Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
Not yet recruiting	`NCT06094829` - Tobacco and Alcohol Influence on Oncogenic Drivers and Somatic Evolution in the Oral Mucosa
Recruiting	`NCT04481256` - TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY	N/A
Active, not recruiting	`NCT02664935` - National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer	Phase 2
Terminated	`NCT02438995` - Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck	Phase 1